发布求助
文献互助 智能选刊 最新文献

Neurodegenerative disease management最新文献

筛选
英文 中文
Multiple system atrophy mimics CASPR2 antibody-associated disease: a case report. 模仿 CASPR2 抗体相关疾病的多系统萎缩：一份病例报告。
IF 2.3
Neurodegenerative disease management Pub Date : 2024-01-01 Epub Date: 2024-09-25 DOI: 10.1080/17582024.2024.2388506
Xiaoli Chen, Li Feng, Jing Li, Hong Jiang
{"title":"Multiple system atrophy mimics CASPR2 antibody-associated disease: a case report.","authors":"Xiaoli Chen, Li Feng, Jing Li, Hong Jiang","doi":"10.1080/17582024.2024.2388506","DOIUrl":"10.1080/17582024.2024.2388506","url":null,"abstract":"<p><p><b>Aim:</b> Multiple system atrophy (MSA) and CASPR2 antibody-associated disease bear their own characteristics.<b>Case presentation:</b> A 58-year-old woman presented with a 26 months history of uncoordinated gait and slurred speech. Her serum was positive for anti-CASPR2 antibodies, and MRI revealed atrophy of the brainstem and cerebellum. She underwent three plasma exchanges (PE) and received high doses of corticosteroids without any apparent effect. Her autonomic dysfunction improved after repetitive transcranial magnetic stimulation. Eventually, a diagnosis of MSA-cerebellar phenotype(MSA-C) was made.<b>Conclusion:</b> With increased availability of tools for neuron antibody detection, physicians need to be aware of the possibility that antibodies may accompany other diseases. This report underscores the modern dilemmas caused by available and extensive neuron antibody testing.</p>","PeriodicalId":19114,"journal":{"name":"Neurodegenerative disease management","volume":"14 3-4","pages":"69-74"},"PeriodicalIF":2.3,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11457613/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142350681","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Refractory anti-NMDAR encephalitis with multiple nosocomial infections: optimizing the therapeutical options. 难治性抗 NMDAR 脑炎合并多种鼻腔感染：优化治疗方案。
IF 2.3
Neurodegenerative disease management Pub Date : 2024-01-01 Epub Date: 2024-08-19 DOI: 10.1080/17582024.2024.2388508
Sachin G Nair, Elezabeth Koshy, Rajender Kandikonda, Sudheeran Kannoth
{"title":"Refractory anti-NMDAR encephalitis with multiple nosocomial infections: optimizing the therapeutical options.","authors":"Sachin G Nair, Elezabeth Koshy, Rajender Kandikonda, Sudheeran Kannoth","doi":"10.1080/17582024.2024.2388508","DOIUrl":"10.1080/17582024.2024.2388508","url":null,"abstract":"<p><p>Nosocomial infections during immunotherapy pose a dilemma in the treatment of anti-N-methyl-D-aspartate receptor (NMDAR) encephalitis, where a lack of consensus guidelines for this rare disease marks a significant gap in the existing knowledge. This case reports about an 18-year-old female diagnosed with anti-NMDAR encephalitis who was found to be refractory to first- and second-line treatment. During her hospital stay, the patient encountered nearly six episodes of infection, which delayed the use of next-line intervention. It was observed that switching over to the next line of treatment during infections may produce sub-therapeutic outcomes. Thereby, the case highlights the need for de-escalation and appropriate selection of immunosuppression therapy during nosocomial infections and how monotherapy with the patient-tolerated first-line agent can be appropriate during infection.</p>","PeriodicalId":19114,"journal":{"name":"Neurodegenerative disease management","volume":" ","pages":"63-67"},"PeriodicalIF":2.3,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11457615/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142000426","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Improvements in quality of life of people with relapsing multiple sclerosis treated with cladribine tablets during the 2-year CLARIFY-MS study: a plain language summary. 在为期2年的clarity - ms研究中，使用克拉德滨片治疗复发性多发性硬化症患者的生活质量改善：简单的语言总结。
IF 2.3
Neurodegenerative disease management Pub Date : 2024-01-01 Epub Date: 2024-12-16 DOI: 10.1080/17582024.2024.2429970
Bruno Brochet, Alessandra Solari, Jeannette Lechner-Scott, Fredrik Piehl, Dawn Langdon, Raymond Hupperts, Krzysztof Selmaj, Francesco Patti, Luis Brieva, Eva Maria Maidal, Nektaria Alexandri, Andrzej Smyk, Axel Nolting, Xavier Montalban, Eva Kubala Havrdova
{"title":"Improvements in quality of life of people with relapsing multiple sclerosis treated with cladribine tablets during the 2-year CLARIFY-MS study: a plain language summary.","authors":"Bruno Brochet, Alessandra Solari, Jeannette Lechner-Scott, Fredrik Piehl, Dawn Langdon, Raymond Hupperts, Krzysztof Selmaj, Francesco Patti, Luis Brieva, Eva Maria Maidal, Nektaria Alexandri, Andrzej Smyk, Axel Nolting, Xavier Montalban, Eva Kubala Havrdova","doi":"10.1080/17582024.2024.2429970","DOIUrl":"10.1080/17582024.2024.2429970","url":null,"abstract":"","PeriodicalId":19114,"journal":{"name":"Neurodegenerative disease management","volume":" ","pages":"193-201"},"PeriodicalIF":2.3,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11730356/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142829526","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Mapping the journey of patients and care partners living with adult-onset leukoencephalopathy with axonal spheroids and pigmented glia: developing a framework for improvements in care. 绘制伴有轴突球和色素小体的成人型白质脑病患者和护理伙伴的心路历程图：制定改善护理的框架。
IF 2.3
Neurodegenerative disease management Pub Date : 2024-01-01 Epub Date: 2024-10-03 DOI: 10.1080/17582024.2024.2404378
Holly A Rutherford, Beth K Rush, Adam Smith, Erin Sullivan, Clarissa Martinez-Rubio, Ali Toumadj, Roberta La Piana, Cynthia Cassandro
{"title":"Mapping the journey of patients and care partners living with adult-onset leukoencephalopathy with axonal spheroids and pigmented glia: developing a framework for improvements in care.","authors":"Holly A Rutherford, Beth K Rush, Adam Smith, Erin Sullivan, Clarissa Martinez-Rubio, Ali Toumadj, Roberta La Piana, Cynthia Cassandro","doi":"10.1080/17582024.2024.2404378","DOIUrl":"10.1080/17582024.2024.2404378","url":null,"abstract":"<p><p><b>Aim:</b> To identify and raise awareness of healthcare service gaps for individuals with adult-onset leukoencephalopathy with axonal spheroids and pigmented glia (ALSP).<b>Materials & methods:</b> An ALSP patient journey map from symptom onset throughout disease course was developed using existing literature, patient and clinician feedback from a structured workshop and community survey data regarding attitudes toward genetic testing.<b>Results:</b> ALSP diagnosis is frequently delayed due to low awareness of this rare condition and symptom overlap with more common neurological conditions. Multiple factors impact patients' decision-making regarding genetic testing for ALSP, symptom management and participation in research studies.<b>Conclusion:</b> These results highlight the challenges faced by individuals with ALSP and should support program development to improve patient care.</p>","PeriodicalId":19114,"journal":{"name":"Neurodegenerative disease management","volume":" ","pages":"161-172"},"PeriodicalIF":2.3,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11524202/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142372376","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Current and future applications of local field potential-guided programming for Parkinson's disease with the Percept™ rechargeable neurostimulator. 利用 Percept™ 可充电神经刺激器对帕金森病进行局部场电位引导编程的当前和未来应用。
IF 2.3
Neurodegenerative disease management Pub Date : 2024-01-01 Epub Date: 2024-09-30 DOI: 10.1080/17582024.2024.2404386
Weerawat Saengphatrachai, Joohi Jimenez-Shahed
{"title":"Current and future applications of local field potential-guided programming for Parkinson's disease with the Percept™ rechargeable neurostimulator.","authors":"Weerawat Saengphatrachai, Joohi Jimenez-Shahed","doi":"10.1080/17582024.2024.2404386","DOIUrl":"10.1080/17582024.2024.2404386","url":null,"abstract":"<p><p>Deep brain stimulation (DBS) has been established as an effective neuromodulatory treatment for Parkinson's disease (PD) with motor complications or refractory tremor. Various DBS devices with unique technology platforms are commercially available and deliver continuous, open-loop stimulation. The Percept™ family of neurostimulators use BrainSense™ technology with five key features to sense local field potentials while stimulating, enabling integration of physiologic data into the routine practice of DBS programming. The newly approved Percept™ rechargeable RC implantable pulse generator offers a smaller, thinner design and reduced recharge time with prolonged recharge interval. In this review, we describe the application of local field potential sensing-based programming in PD and highlight the potential future clinical implementation of closed-loop stimulation using the Percept™ RC implantable pulse generator.</p>","PeriodicalId":19114,"journal":{"name":"Neurodegenerative disease management","volume":" ","pages":"131-147"},"PeriodicalIF":2.3,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11524207/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142350678","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Walking performance differs between people with multiple sclerosis who perform distinct types of exercise. 多发性硬化症患者在进行不同类型的运动时，步行表现也不尽相同。
IF 2.3
Neurodegenerative disease management Pub Date : 2024-01-01 Epub Date: 2024-08-19 DOI: 10.1080/17582024.2024.2389037
Kristin A Johnson, Victoria M Bandera, Manfred Diehl, Heather J Leach, Brett W Fling
{"title":"Walking performance differs between people with multiple sclerosis who perform distinct types of exercise.","authors":"Kristin A Johnson, Victoria M Bandera, Manfred Diehl, Heather J Leach, Brett W Fling","doi":"10.1080/17582024.2024.2389037","DOIUrl":"10.1080/17582024.2024.2389037","url":null,"abstract":"<p><p><b>Aim:</b> To determine whether walking performance differed between people with multiple sclerosis (MS) who performed distinct types, volumes and intensities of exercise.<b>Materials & methods:</b> Forty-five people with relapsing-remitting MS performed two trials of the 2-min walk test, one at a preferred speed and another at a fast speed. Gait metrics were measured by wireless inertial sensors. Participants reported the type (aerobic, resistance), volume and intensity of exercise performed.<b>Results:</b> Walking speed reserve and gait variability were better in participants who performed combined aerobic and resistance exercises compared with those who performed aerobic-only exercise.<b>Conclusion:</b> Walking performance differs in people with mild MS disability based on the type and volume of exercise performed.</p>","PeriodicalId":19114,"journal":{"name":"Neurodegenerative disease management","volume":" ","pages":"75-85"},"PeriodicalIF":2.3,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11457625/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142000427","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Tofersen for SOD1 ALS. Tofersen 用于 SOD1 ALS。
IF 2.3
Neurodegenerative disease management Pub Date : 2024-01-01 Epub Date: 2024-09-27 DOI: 10.1080/17582024.2024.2402216
William H Everett, Robert C Bucelli
{"title":"Tofersen for SOD1 ALS.","authors":"William H Everett, Robert C Bucelli","doi":"10.1080/17582024.2024.2402216","DOIUrl":"10.1080/17582024.2024.2402216","url":null,"abstract":"<p><p>Amyotrophic lateral sclerosis (ALS) is a neurodegenerative condition affecting the motor system. The heterogenous nature of ALS complicates trial design. Genetic forms of ALS present an opportunity to intervene in a less heterogeneous population. ALS associated with gain of function mutations in <i>SOD1</i> make 'knock-down' strategies an attractive therapeutic approach. Tofersen, an antisense oligonucleotide that reduces expression of SOD1 via RNAase mediated degradation of <i>SOD1</i> mRNA, has shown robust effects on ALS biomarkers. While a Phase III trial of tofersen failed to meet its primary end point, open label extension data suggests that tofersen slows progression of SOD1 ALS.</p>","PeriodicalId":19114,"journal":{"name":"Neurodegenerative disease management","volume":" ","pages":"149-160"},"PeriodicalIF":2.3,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11524200/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142350679","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Bone marrow mesenchymal stem cell-derived extracellular vesicle infusion for amyotrophic lateral sclerosis. 骨髓间充质干细胞衍生的细胞外囊泡输注治疗肌萎缩性脊髓侧索硬化症。
IF 2.3
Neurodegenerative disease management Pub Date : 2024-01-01 Epub Date: 2024-05-28 DOI: 10.1080/17582024.2024.2344396
Joshua J Crose, Arezou Crose, John T Ransom, Amy L Lightner
{"title":"Bone marrow mesenchymal stem cell-derived extracellular vesicle infusion for amyotrophic lateral sclerosis.","authors":"Joshua J Crose, Arezou Crose, John T Ransom, Amy L Lightner","doi":"10.1080/17582024.2024.2344396","DOIUrl":"10.1080/17582024.2024.2344396","url":null,"abstract":"<p><p><b>Background:</b> In this pilot safety study, we hypothesized that a human bone marrow stem cell-derived extracellular vesicle (hBM-MSC EV) investigational product (IP) would be safe and exhibit potential efficacy in amyotrophic lateral sclerosis (ALS) patients.<b>Methods:</b> Ten ALS patients received two 10-ml intravenous infusions of the IP given 1 month apart and evaluated over 3 months.<b>Results:</b> There were no serious adverse events or adverse events related to the IP and 30% of subjects' ALS functional rating scale-revised (ALSFRS-R) scores did not decline.<b>Conclusion:</b> HBM-MSC EVs appear safe in ALS patients. This early investigation suggests a controlled study of EVs for the treatment of ALS is warranted.</p>","PeriodicalId":19114,"journal":{"name":"Neurodegenerative disease management","volume":"14 3-4","pages":"111-117"},"PeriodicalIF":2.3,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11457643/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142350680","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Neurofilament light chain: a biomarker at the crossroads of clarity and confusion for gene-directed therapies. 神经丝蛋白轻链：处于基因导向疗法清晰与混乱交叉点的生物标志物。
IF 2.3
Neurodegenerative disease management Pub Date : 2024-01-01 Epub Date: 2024-11-15 DOI: 10.1080/17582024.2024.2421738
Michael Christian A Virata, Jesus Alfonso Catahay, Giuseppe Lippi, Brandon M Henry
{"title":"Neurofilament light chain: a biomarker at the crossroads of clarity and confusion for gene-directed therapies.","authors":"Michael Christian A Virata, Jesus Alfonso Catahay, Giuseppe Lippi, Brandon M Henry","doi":"10.1080/17582024.2024.2421738","DOIUrl":"10.1080/17582024.2024.2421738","url":null,"abstract":"<p><p>Neurofilament light chain (NfL) is a promising biomarker for neurodegenerative diseases, measurable in both CSF and blood upon neuroaxonal damage. While CSF analysis was traditionally used, blood-based assays now offer a less invasive alternative. NfL levels correlate with disease severity and progression in conditions like Alzheimer's disease, amyotrophic lateral sclerosis, multiple sclerosis and Huntington's disease. Clinical trials demonstrate its utility as a pharmacodynamic biomarker in MS and ALS. The FDA's approval of Tofersen for SOD1-ALS based on NfL reduction underscores its growing acceptance as surrogate marker. However, challenges remain in standardizing assays, interpreting clinical correlations, low specificity and understanding the dynamics between CSF and blood NfL levels. Addressing these issues is crucial for maximizing NfL's potential in neurodegenerative disease management.</p>","PeriodicalId":19114,"journal":{"name":"Neurodegenerative disease management","volume":" ","pages":"227-239"},"PeriodicalIF":2.3,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11703492/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142639061","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Impact of a keto diet on symptoms of Parkinson's disease, biomarkers, depression, anxiety and quality of life: a longitudinal study. 酮饮食对帕金森病症状、生物标志物、抑郁、焦虑和生活质量的影响：一项纵向研究。
IF 2.3
Neurodegenerative disease management Pub Date : 2024-01-01 Epub Date: 2024-06-13 DOI: 10.1080/17582024.2024.2352394
Melanie M Tidman, Dawn Reid White, Tim A White
{"title":"Impact of a keto diet on symptoms of Parkinson's disease, biomarkers, depression, anxiety and quality of life: a longitudinal study.","authors":"Melanie M Tidman, Dawn Reid White, Tim A White","doi":"10.1080/17582024.2024.2352394","DOIUrl":"10.1080/17582024.2024.2352394","url":null,"abstract":"<p><p><b>Aim:</b> Evidence suggests low-carbohydrate diets (LCHF) may assist in treating neurodegenerative diseases such as Parkinson's disease (PD); however, gaps exist in the literature.<b>Patients & methods:</b> We conducted a small 24-week pilot study to investigate the effects of an LCHF diet on motor and nonmotor symptoms, health biomarkers, anxiety, and depression in seven people with PD. We also captured patient experiences during the process (quality of life [QoL]).<b>Results:</b> Participants reported improved biomarkers, enhanced cognition, mood, motor and nonmotor symptoms, and reduced pain and anxiety. Participants felt improvements enhanced their QoL.<b>Conclusion:</b> We conclude that an LCHF intervention is safe, feasible, and potentially effective in mitigating the symptoms of this disorder. However, more extensive randomized controlled studies are needed to create generalizable recommendations.</p>","PeriodicalId":19114,"journal":{"name":"Neurodegenerative disease management","volume":" ","pages":"97-110"},"PeriodicalIF":2.3,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11457624/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141311267","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
首页 上一页 下一页 尾页
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整，为了账户安全，请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
请完成安全验证×
相关产品
×
本文献相关产品
联系我们：info@booksci.cn Book学术提供免费学术资源搜索服务，方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号：481959085
Book学术官方微信